Clinical Trials Logo

Optic Atrophy, Hereditary, Leber clinical trials

View clinical trials related to Optic Atrophy, Hereditary, Leber.

Filter by:

NCT ID: NCT03406104 Completed - Clinical trials for Leber Hereditary Optic Neuropathy

RESCUE and REVERSE Long-term Follow-up

RESTORE
Start date: January 9, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the long-term safety and efficacy of GS010, a gene therapy, and assess the quality of life in subjects with LHON due to the G11778A ND4 mitochondrial mutation and who were treated in the Rescue or Reverse studies.

NCT ID: NCT03295071 Completed - Clinical trials for Leber Hereditary Optic Neuropathy

REALITY LHON Registry

REALITY
Start date: January 3, 2018
Phase:
Study type: Observational [Patient Registry]

This study is a multi-country retrospective and cross-sectional observational study of affected LHON subjects, based on retrospective subjects' medical chart abstractions and cross-sectional administration of patient-reported outcomes (PROs).

NCT ID: NCT03293524 Active, not recruiting - Clinical trials for Leber Hereditary Optic Neuropathy

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

REFLECT
Start date: March 12, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the safety and efficacy of GS010, a gene therapy, in improving the retina functional & structural outcomes in subjects with LHON due to the G11778A ND4 mitochondrial mutation when vision loss duration is present up to one year.

NCT ID: NCT03153293 Active, not recruiting - Clinical trials for Leber Hereditary Optic Neuropathy

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Start date: December 27, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This study is meant to evaluate the safety and efficacy of rAAV2-ND4 treatment for Leber hereditary optic neuropathy with the G11778A mutation in mitochondrial DNA.

NCT ID: NCT03011541 Recruiting - Glaucoma Clinical Trials

Stem Cell Ophthalmology Treatment Study II

SCOTS2
Start date: January 2016
Phase: N/A
Study type: Interventional

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

NCT ID: NCT02796274 Completed - Clinical trials for Leber's Hereditary Optic Neuropathy (LHON)

Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)

Start date: May 2016
Phase:
Study type: Observational

The purpose of this survey is to collect visual acuity data from patients with LHON in order to establish the clinical course (natural history) and visual acuity outcomes in patients with a genetically confirmed diagnosis of LHON. In addition, this survey will generate data that will serve as comparator for the open-label study SNT-IV-006.

NCT ID: NCT02774005 Completed - Clinical trials for Leber's Hereditary Optic Neuropathy (LHON)

Study to Assess the Efficacy and Safety of Raxone in LHON Patients

LEROS
Start date: May 2016
Phase: Phase 4
Study type: Interventional

LEROS is an open-label interventional Phase IV study, designed to further assess the efficacy and safety of Raxone® in the long-term treatment of LHON patients.

NCT ID: NCT02771379 Completed - Clinical trials for Leber's Hereditary Optic Neuropathy (LHON)

Post Authorisation Safety Study With Raxone in LHON Patients

PAROS
Start date: September 2016
Phase:
Study type: Observational

This study is a multicentre, prospective, non-interventional post-authorisation safety study (PASS) of the clinical outcomes for patients with LHON treated with Raxone®. No medication will be provided as part of this study. Raxone® will be obtained through commercial channels.

NCT ID: NCT02693119 Completed - Clinical trials for Leber's Hereditary Optic Neuropathy

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy

Start date: March 2016
Phase: Phase 2
Study type: Interventional

This is a Phase 2, prospective, randomized, double-masked, vehicle controlled, single-center study in approximately 12 subjects with LHON to evaluate safety, tolerability and efficacy of elamipretide (MTP-131) topical ophthalmic solution in this patient population. At the conclusion of 52 weeks of treatment, subjects will be offered the opportunity to enter an Open Label Extension for up to 48 additional weeks of treatment.

NCT ID: NCT02300753 No longer available - Clinical trials for Leber's Hereditary Optic Neuropathy

Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]

Start date: n/a
Phase: N/A
Study type: Expanded Access

Expanded access Protocol to treat LHON subjects with EPI743